July 18, 2022 — The Baszucki Brain Research Fund is pleased to announce that five science teams around the globe have received funding to study ketogenic metabolic interventions for bipolar disorder, schizophrenia and major depressive disorder.

July 7, 2022 — This 5-minute NBC segment showcases another promising area the Baszuckis have invested in: a more targeted approach to Transcranial Magnetic Stimulation (TMS), facilitated by Magnus Medical. The company was able to end their FDA study early because the results were so impactful — 80% of depressed patients went into remission.